iwNHL 2017 highlights: the PDX model
Where are we with precision medicine for CLL?
Are complex karyotypes reliable prognostic markers for CLL?
Impressive results from phase 3 RESONATE trial in CLL
How to manage relapsed/refractory MCL - new agents and unmet needs